Everest reaches new heights on growing drug sales
The innovative drug maker said its revenue soared more than 850% last year to between 124 million yuan and 126 million yuan Key Takeaways: Everest Medicines’ revenue soared nine-fold last…
Adlai Nortye dives in Nasdaq debut, as key product faces hurdles
Shares of the drug maker that licenses its products from other companies lost more than half their value in the two weeks after their listing Key Takeaways: Newly listed Adlai…
ImmuneOnco banks on cutting-edge cancer drugs to attract IPO cash
The biopharma wants to use IPO proceeds to bring its cancer immunotherapies to market, having already built a lofty valuation with backers such as Eli Lilly Key Takeaways: ImmuneOnco’s main…
Everest Medicines Descends to New Depths on String of Bad News
The drug maker’s shares hit all-time lows after it announced the loss of a key product, poor financial results and the resignation of its CEO Key Takeaways: The CEO of…
RELATED ARTICLES
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK -
Akeso marks profit milestone with swift rights issue
9926.HK
-
CSPC Pharma weighs up diet drug for bigger bottom line
1093.HK
-
With no cure in sight, drugs firm LianBio begins exit strategy
LIAN.US
- InSilico seeks IPO boost to get AI drugs over the line
-
HBM gets health boost from drug licensing deals
2142.HK
